Cargando…
Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
OBJECTIVE: To assess whether the use of dipeptidyl peptidase-4 inhibitors is associated with the incidence of inflammatory bowel disease in patients with type 2 diabetes. DESIGN: Population based cohort study. SETTING: More than 700 general practices contributing data to the United Kingdom Clinical...
Autores principales: | Abrahami, Devin, Douros, Antonios, Yin, Hui, Yu, Oriana Hoi Yun, Renoux, Christel, Bitton, Alain, Azoulay, Laurent |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group Ltd.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861502/ https://www.ncbi.nlm.nih.gov/pubmed/29563098 http://dx.doi.org/10.1136/bmj.k872 |
Ejemplares similares
-
Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study
por: Abrahami, Devin, et al.
Publicado: (2018) -
Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: a UK population-based cohort study
por: Pradhan, Richeek, et al.
Publicado: (2023) -
A66 PROTON PUMP INHIBITORS AND THE RISK OF INFLAMMATORY BOWEL DISEASE: A REAL WORLD POPULATION-BASED COHORT STUDY
por: Yanofsky, R P, et al.
Publicado: (2023) -
Response by Abrahami et al to letter regarding article ‘Proton pump inhibitors and risk of colorectal cancer’
por: Abrahami, Devin, et al.
Publicado: (2022) -
New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)